Thomassen I, Lemmens VE, Nienhuijs SW, et al. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas. 2013;42:72–5.

Article  PubMed  Google Scholar 

Yamada S, Fujii T, Yamamoto T, et al. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. J Gastrointest Oncol. 2021;12:S110–7.

Article  PubMed  PubMed Central  Google Scholar 

Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 8th ed. Union for International Cancer Control: Kanehara & Co., Ltd; 2017.

Google Scholar 

Ishida M, Fujii T, Kishiwada M, et al. Japanese classification of pancreatic carcinoma by the japan pancreas society. J Hepatobil Pancreat Sci. 2024. https://doi.org/10.1002/jhbp.12056.

Article  Google Scholar 

Tsuchida H, Fujii T, Mizuma M, et al. Committee of clinical research, Japan pancreas society. prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: a nationwide, cancer registry-based study from the Japan pancreas society. Surgery. 2019;166(6):997–1003.

Article  PubMed  Google Scholar 

Wang-Gillam A, Li CP, Bodoky G, Dean A, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–57.

Article  CAS  PubMed  Google Scholar 

Japanese Society of Peritoneal Marignancy. Clinical practice guidelines for peritoneal malignancy 2021. Tokyo: Kanehara & Co., Ltd.; 2021.

Google Scholar 

Mitachi K, Ariake K, Motoi F, et al. Conversion surgery for positive peritoneal washing cytology in pancreatic cancer. BMJ Case Rep. 2019. https://doi.org/10.1136/bcr-2019-229993.

Article  PubMed  PubMed Central  Google Scholar 

Su YY, Chiang NJ, Tsai HJ, et al. The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: real-world experience in a Taiwanese cohort. Sci Rep. 2020;10(1):7420.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kikuchi K, Umemura A, Nitta H, et al. A case of pathological complete response with liposomal irinotecan + 5-FU/LV for unresectable locally advanced pancreatic cancer. Surg Case Rep. 2022;8(1):192.

Article  PubMed  PubMed Central  Google Scholar 

Igarashi T, Fukasawa M, Watanabe T, et al. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology. Ann Gastroenterol Surg. 2023;8(1):124–32.

Article  PubMed  PubMed Central  Google Scholar 

Fukasawa M, Watanabe T, Tanaka H, et al. Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytology. J Hepatobil Pancreat Sci. 2023;30(11):1261–72.

Article  Google Scholar 

Yoshitomi H, Takano S, Furukawa K, et al. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Surg Today. 2019;49(11):894–906.

Article  PubMed  Google Scholar 

Lee M, Kang JS, Kim H, et al. Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. J Hepatobil Pancreat Sci. 2023;30(1):111–21.

Article  Google Scholar 

Igarashi T, Yamada S, Hoshino Y, et al. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual-center study. Ann Gastroenterol Surg. 2022;7(1):157–66.

Article  PubMed  PubMed Central  Google Scholar 

Hashimoto D, Satoi S, Fujii T, et al. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the joint meeting of the international association of pancreatology (IAP) & the Japan pancreas society (JPS) 2022 in Kyoto. Pancreatology. 2023;23(6):682–8.

Article  PubMed  Google Scholar 

Satoi S, Yamamoto T, Yamaki S, Sakaguchi T, Sekimoto M. Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2020;4:6–13.

Article  PubMed  Google Scholar 

Ushida Y, Inoue Y, Oba A, et al. Optimizing indications for conversion surgery based on analysis of 454 consecutive Japanese cases with unresectable pancreatic cancer who received modified FOLFIRINOX or gem citabine plus nab-paclitaxel: a single-center retrospective study. Ann Surg Oncol. 2022;29:5038–50.

Article  PubMed  Google Scholar 

Nagai M, Wright MJ, Ding D, et al. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. J Hepatobil Pancreat Sci. 2023;30(8):1025–35.

Article  Google Scholar 

Mataki Y, Kurahara H, Idichi T, et al. Clinical benefits of conversion surgery for unresectable pancreatic ductal adenocarcinoma: a single-institution, retrospective analysis. Cancers (Basel). 2021;13(5):1057.

Article  PubMed  Google Scholar 

Yasuda S, Nagai M, Terai T, et al. Essential updates 2021/2022: surgical outcomes of oligometastasis in pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg. 2023;7(3):358–66.

Article  PubMed  PubMed Central  Google Scholar